In the future, we anticipate a phase-1 clinical trial that evaluates the safety of BUB1 inhibitor BAY1816032 as a monotherapy and in combination with cisplatin, paclitaxel, PARP inhibitors, and radiotherapy in patients with lung cancer. Here, BUB1 is linked to lung carcinoma.